Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.

Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L.

J Thromb Haemost. 2011 Nov;9(11):2229-34. doi: 10.1111/j.1538-7836.2011.04493.x.

PMID:
21883884
2.

More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.

Santagostino E.

Haemophilia. 2013 Jan;19 Suppl 1:8-11. doi: 10.1111/hae.12050. Review.

PMID:
23278994
3.

Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.

Kurth MA, Dimichele D, Sexauer C, Sanders JM, Torres M, Zappa SC, Ragni M, Leonard N.

Haemophilia. 2008 Jan;14(1):50-5. Epub 2007 Oct 18. Erratum in: Haemophilia. 2008 Jul;14(4):878. Haemophilia. 2008 Mar;14(2):414.

PMID:
17941829
4.

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.

Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E.

Haemophilia. 2014 Jan;20(1):83-91. doi: 10.1111/hae.12263. Epub 2013 Nov 19.

5.
6.

Immune tolerance induction in patients with hemophilia A.

Astermark J.

Thromb Res. 2011 Jan;127 Suppl 1:S6-9. doi: 10.1016/j.thromres.2010.10.006. Epub 2010 Nov 5.

PMID:
21056905
7.

Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.

Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.

Haemophilia. 2013 Mar;19(2):281-6. doi: 10.1111/hae.12018. Epub 2012 Oct 8.

PMID:
23038998
8.
9.
10.

Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.

Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; RITS-FITNHES Study Group.

Haemophilia. 2007 Jul;13(4):373-9.

PMID:
17610550
11.

The role of VWF for the success of immune tolerance induction.

Kreuz W.

Thromb Res. 2008;122 Suppl 2:S7-S12. doi: 10.1016/S0049-3848(08)70003-3. Review.

PMID:
18549910
12.

ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.

Oldenburg J, Austin SK, Kessler CM.

Haemophilia. 2014 Sep;20 Suppl 6:17-26. doi: 10.1111/hae.12466. Review.

PMID:
24975701
13.

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?

Ettingshausen CE, Kreuz W.

Haemophilia. 2013 Jan;19 Suppl 1:12-7. doi: 10.1111/hae.12051. Review.

PMID:
23278995
14.

VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.

Gringeri A.

Haemophilia. 2007 Dec;13 Suppl 5:73-7. doi: 10.1111/j.1365-2516.2007.01579.x.

PMID:
18078402
15.

Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.

Gringeri A, Ofosu FA, Grancha S, Oldenburg J, Ewing NP, Federici AB.

Haemophilia. 2012 May;18(3):469-75. doi: 10.1111/j.1365-2516.2011.02655.x. Epub 2011 Sep 22.

PMID:
21943193
16.

Role of von Willebrand factor in immune tolerance induction.

Ettingshausen CE, Kreuz W.

Blood Coagul Fibrinolysis. 2005 Apr;16 Suppl 1:S27-31. Review.

PMID:
15849524
17.

A review of immune tolerance induction with Haemate P in haemophilia A.

Escuriola Ettingshausen C, Kreuz W.

Haemophilia. 2014 May;20(3):333-9. doi: 10.1111/hae.12288. Epub 2013 Oct 24. Review.

18.

Epidemiology of inhibitors and current treatment strategies.

Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group.

Haematologica. 2003 Jun;88(6):EREP04. Review.

PMID:
12826530
19.

Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.

Rivolta GF, Di Perna C, Franchini M, Riccardi F, Ippolito L, Lombardi M, Tagliaferri A.

Blood Transfus. 2010 Jan;8(1):66-8. doi: 10.2450/2009.0078-09. No abstract available.

20.

The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Auerswald G, Spranger T, Brackmann HH.

Haematologica. 2003 Jun;88(6):EREP05. Review.

PMID:
12826531
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk